Advertisement

Topics

BIND Biosciences, Inc. Company Profile

06:17 EDT 23rd June 2018 | BioPortfolio

BIND Biosciences, Inc., is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering platform to produce best in class drugs to provide significant improvement in the treatment of patients with serious diseases. BIND’s platform enables the design, engineering and manufacturing of therapeutic targeted nanoparticles with unprecedented control over drug pharmacokinetics, biodistribution, and cell- or tissue-specific targeting. Medicinal Nanoengineering complements medicinal chemistry to enable predictable, cost effective, and rapid development of breakthrough products with superior efficacy and safety profiles. Product opportunities include enabling or expediting the development of pipeline molecules as well as improving performance, expanding indications or life cycle extension for mid- and late-stage products. BIND’s initial product development efforts are in the areas of oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics. BIND’s lead program, BIND-014, targets a surface protein upregulated in solid tumors and is planned to enter clinical development in 2H 2010.


News Articles [679 Associated News Articles listed on BioPortfolio]

Not quite a 'double bind' for minority women in science

Many studies have shown that both minority and women scientists face disadvantages in reaching the highest levels of their careers. So it would make sense that minority women would face a 'double bind...

ASC Biosciences, Inc. announces ad dates for first television commercial

About ASC Biosciences, Inc.ASC Biosciences, Inc. ("ASC" or the "Company") is a development stage biotechnology company with a proprietary adult stem cell platform capable Read more...

SOLID BIOSCIENCES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Solid Biosciences Inc. to Contact The Firm

NEW YORK, NY / ACCESSWIRE / April 9, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Solid Biosciences Inc. ("Solid Biosciences" or th...

Kuros Biosciences Ltd.: Kuros Biosciences weitet Lizenzabkommen mit Checkmate aus

Schlieren (Zürich), Schweiz, 8. Januar 2018 Kuros Biosciences weitet Lizenzabkommen mit Checkmate aus Kuros Biosciences AG (SIX: KURN) gibt die Ausdehnung des exklusiven Lizenzabkommens mit Checkm...

African Women for Biosciences Platform Launched

Women in biosciences remain grossly under represented in leadership and decision-making levels, limiting contribution of scientific research to national development. A new platform - the African Women...

Apricus Biosciences, Inc.: Apricus Biosciences Announces Proposed Public Offering

SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that ...

Apricus Biosciences, Inc.: Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros

Company Evaluating Deficiencies and Potential Path Forward SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative me...

Double-bridged peptides bind any disease target

Scientists have developed a new type of 'double-bridged peptide' that can be tailored to bind tightly to disease targets of interest. The peptides' highly efficient binding, combined with their small ...

Drugs and Medications [22 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

Clinical Trials [104 Associated Clinical Trials listed on BioPortfolio]

Long-Term Follow Up Study

The LTFU study will conduct a naturalistic follow up of the well characterized CAN-BIND study population of patients every six months and continuing over a five-year period. This will prov...

HepaStem Long-Term Safety Registry

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Bi...

A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer

BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation positive or squamous cel...

Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum

The purpose of this study is to test the safety of a new medicine called antibody 8H9 injected into the lining of the abdomen or peritoneum, where the tumor is. This medicine is an antibod...

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Ce...

Companies [383 Associated Companies listed on BioPortfolio]

BIND Biosciences, Inc.

BIND Biosciences, Inc., is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering platform to produce best in class drugs to provide signif...

BIND Therapeutics, Inc.

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering pl...

BIND Therapeutics

BIND Therapeutics is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BIND’s Me...

Alzeca Biosciences, Inc.

Alzeca Biosciences is an early-stage company focused on developing novel, proprietary, targeted MRI imaging agents for the early diagnosis of Alzheimer’s disease and other ne...

BIND Therapeutics and Navidea Biopharmaceuticals

BIND Therapeutics is a clinical-stage nanomedicine platform company developing a pipeline of Accurins™, its novel targeted therapeutics designed to increase the concentration...

More Information about "BIND Biosciences, Inc." on BioPortfolio

We have published hundreds of BIND Biosciences, Inc. news stories on BioPortfolio along with dozens of BIND Biosciences, Inc. Clinical Trials and PubMed Articles about BIND Biosciences, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BIND Biosciences, Inc. Companies in our database. You can also find out about relevant BIND Biosciences, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record